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Editorial
Since the introduction of Highly Active An-
ti-Retroviral Therapy (HAART) in 1996, life qual-
ity and life expectance of People Living with 
HIV (PLWH) dramatically improved. An infection 
leading to death in just after a few months after the 
first appearance of its symptoms became a chronic 
infection, which allowed to lead an almost normal 
life to people who acquired it. Consequently, we 
assisted to an increase of chronic pathologies, 
associated to ageing, to the natural history of the 
HIV infection and to adverse effects of the drugs1-6.
Among the chronic disorders, which prevalence 
has increased in PLWH, we find neoplasms7-11. In 
the last twenty years, the so-called post-HAART 
era, the incidence of AIDS-defining cancers, such 
as Kaposi’s Sarcoma (KS), Non-Hodgkin Lympho-
ma (NHL) and HPV-related cervical cancer, has 
reduced, even though it is still higher than the gen-
eral population. On the other hand, the incidence 
of non-AIDS-defining cancers (NADCs), e.g. lung 
cancer, skin cancer, prostate cancer, breast cancer, 
anal cancer, colon cancer, and hepatocellular car-
cinoma (HCC), increased12,13.
The HIV infection alone is a risk factor for 
cancers, being them related to persistent inflam-
mation and immune dysregulation. As a matter of 
fact, HIV protein tat action leads to an increase of 
pro-inflammatory cytokines such as IL-6, IL-8, 
IL-12 and TNF-a. A high concentration of this 
cytokines is often found associated to pre-malig-
nant mucosal lesions. 
Moreover, PLWH are more often smokers 
and alcohol consumers than the general popu-
lation, adding other risk factors to an already 
unbalanced scale. It is then easy to see how 
PLWH are in constant need of being screened 
for cancers. A need that is recognized by the 
scientific community, which clearly regulated 
times and ways to perform said screening tests 
including them in international and national 
guidelines14-16.
Screening tests used to early detect neoplasms 
in PLWH are the same tests applied to the gener-
al population: mammography for breast cancer in 
women aged 50-70 in Europe or more than 40-year-
old in the United States; digital rectum examination 
(DRE) and prostate specific antigen (PSA) to detect 
prostate cancer in men aged > 50 years; fecal occult 
blood, flexible recto-sigmoïdoscopy and colonosco-
py for colorectal cancer in people aged 50-75 years 
in Europe or > 50 years in the US; low-dose CT 
chest scan for lung cancer in people smoking more 
than 30 pack/years or ex-smokers who quit less than 
15 years before the examination; Papanicolau (PAP) 
test and colposcopy to identify cervical squamous 
cell cancer; PAP test and high resolution anoscopy 
to detect anal cancer, especially in men who have 
sex with men (MSM) and women with a positive 
cervical PAP test. The timings are slightly different, 
though: it is recommended for PLWH to undergo 
screening tests more often than the general popu-
lation, once a year for most of them14, 16 (Table 1). 
However, access and adherence to screening tests 
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are often suboptimal and PLWH still come to a doc-
tor attention when they are symptomatic, complain-
ing of loss of weight, asthenia and fever despite their 
adherence to the combined Anti-Retroviral Therapy 
(cART). Sadly, their complaints often come from 
an advanced stage neoplasm. Moreover, PLWH 
are ever more frequently affected than the general 
population by rare and more aggressive forms of tu-
mors, such as HPV-related head and neck squamous 
cell carcinoma (HNSCC) and bladder carcinoma, 
for which screening tests are not yet available17 
It is clear how, in this age full of technological 
revolutions, with new drugs and new methods of 
administration, we should try to achieve the highest 
screening coverage for the wellbeing of our patients. 
It is not admissible anymore to lose a battle without 
even trying to fight it.
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TABLE 1. Screening tests differences between general population and PLWH.
Cancer Screening Test General Population PLWH
     
Anal Anal PAP test Not recommended MSM, once a year
 Anoscopy  Women with abnormal cervical 
    PAP smear, once a year
   MSM, if abnormal PAP smear
Breast Mammography Women > 50-year-old,  Women > 50-year old, once a year
 Breast MRI  every two years
   high-risk < 40-year-old 
Cervical PAP test Women > 25-year-old,  Once a year after HIV
 Colposcopy  every two years  infection diagnosis
  If abnormal PAP test 
Colorectal FOB Every year Same as general population
 Rectal sigmoidoscopy Every five years
 Colonoscopy Every ten years 
Hepatocellular Hepatic ultrasounds If liver cirrhosis for every cause If HIV/HCV or HIV/HBV coinfection,
 α-fetoprotein If HBV or HCV infection  with cirrhosis
  If Asian, men > 40-year-old If HIV/HBV coinfection,
   or women > 50-year-old   when HBV-DNA is detectable
  Every 6 months Every 6-12 months  
Lung Low-dose > 55-year-old with > 40-year-old with
  CT chest scan > 30 pack/year smoking history > 30 pack/year smoking history
  Active or cessation < 15 year Active or cessation < 15 year 
   Once a year
Prostate DRE Population-based screening Men > 50-year-old
 PSA  is not recommended (IC)* Once a year
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